Open AccessProtamine sulfate during transcatheter aortic valve implantation (PS TAVI) — a single-center, single-blind, randomized placebo-controlled trial
Author(s) -
Karol Zbroński,
Kajetan Grodecki,
Roksana Gozdowska,
Ewa Ostrowska,
Julia Wysińska,
Bartosz Rymuza,
Piotr Ścisło,
Radosław Wilimski,
Janusz Kochman,
Krzysztof J. Filipiak,
Grzegorz Opolski,
Ze Huczek
Publication year - 2021
Publication title -
kardiologia polska
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.527
H-Index - 34
eISSN - 1897-4279
pISSN - 0022-9032
DOI - 10.33963/kp.a2021.0070
Subject(s) - medicine , clinical endpoint , protamine sulfate , randomized controlled trial , placebo , surgery , odds ratio , single center , population , confidence interval , heparin , anesthesia , protamine , alternative medicine , environmental health , pathology
Bleeding complications after transcatheter aortic valve implantation (TAVI) negatively affect the post-procedural prognosis. Routine use of protamine sulfate (PS) to reverse unfractionated heparin after TAVI was never assessed in a randomized controlled trial.